Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
| Line 20: | Line 20: | ||
*In another series, 48% of individuals with cancer had a PSAD >0.15 ng/ml.<ref name=pmid22482342>{{Cite journal | last1 = Aganovic | first1 = D. | last2 = Prcic | first2 = A. | last3 = Kulovac | first3 = B. | last4 = Hadziosmanovic | first4 = O. | title = Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. | journal = Med Arh | volume = 66 | issue = 1 | pages = 41-4 | month = | year = 2012 | doi = | PMID = 22482342 }} | *In another series, 48% of individuals with cancer had a PSAD >0.15 ng/ml.<ref name=pmid22482342>{{Cite journal | last1 = Aganovic | first1 = D. | last2 = Prcic | first2 = A. | last3 = Kulovac | first3 = B. | last4 = Hadziosmanovic | first4 = O. | title = Influence of the prostate volume, prostate specific antigen density and number of biopsy samples on prostate cancer detection. | journal = Med Arh | volume = 66 | issue = 1 | pages = 41-4 | month = | year = 2012 | doi = | PMID = 22482342 }} | ||
</ref> | </ref> | ||
* | *Differences between races have been noted in one study; in those without prostate cancer:<ref name=pmid8998182/> | ||
**0.19 +/- 0.03 ng/ml (blacks). | **0.19 +/- 0.03 ng/ml (blacks). | ||
**0.11 +/- 0.01 ng/ml (whites). | **0.11 +/- 0.01 ng/ml (whites). | ||
PSAD is a better predictor than (unadjusted) serum PSA for: | |||
*Gleason score upgrading on [[prostatectomy]].<ref>{{cite journal |author=Sfoungaristos S, Katafigiotis I, Perimenis P |title=The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era |journal=Can Urol Assoc J |volume=7 |issue=11-12 |pages=E722–7 |year=2013 |pmid=24282465 |pmc=3840515 |doi=10.5489/cuaj.374 |url=}}</ref> | *Gleason score upgrading on [[prostatectomy]].<ref>{{cite journal |author=Sfoungaristos S, Katafigiotis I, Perimenis P |title=The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era |journal=Can Urol Assoc J |volume=7 |issue=11-12 |pages=E722–7 |year=2013 |pmid=24282465 |pmc=3840515 |doi=10.5489/cuaj.374 |url=}}</ref> | ||
*Benign prostate gland versus [[prostate cancer]].<ref name=pmid1371554>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref><ref>{{cite journal |author=Verma A, St Onge J, Dhillon K, Chorneyko A |title=PSA density improves prediction of prostate cancer |journal=Can J Urol |volume=21 |issue=3 |pages=7312–21 |year=2014 |month=June |pmid=24978363 |doi= |url=}}</ref> | *Benign prostate gland versus [[prostate cancer]].<ref name=pmid1371554>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref><ref>{{cite journal |author=Verma A, St Onge J, Dhillon K, Chorneyko A |title=PSA density improves prediction of prostate cancer |journal=Can J Urol |volume=21 |issue=3 |pages=7312–21 |year=2014 |month=June |pmid=24978363 |doi= |url=}}</ref> | ||